0007) significantly predicts low fibrinogen level. In non-cholestatic liver disease, K, R, AA and MA (p < 0.005) all significantly predict low fibrinogen level. None of the cholestatic liver disease Staurosporine order patients developed thrombotic complications (0/13). 8.7% of non-cholestatic liver disease patients (9/103) developed pre- or post-transplant thrombosis (portal vein or other systemic thrombosis). The only significant predictor of thrombosis is low INR (p = 0.04). Conclusion: We found significant differences between coagulation profiles of cholestatic liver disease

versus non-cholestatic liver disease. In non-cholestatic liver disease, rising MELD predicts abnormal TEG scores (K, R, AA and MA) and decreasing fibrinogen level. In cholestatic liver disease, rising MELD only significantly correlates with rising INR and not with TEG or traditional coagulation tests (including fibrinogen level). When comparing TEG against traditional coagulation PF-562271 studies, we found in cholestatic liver disease, low MA predicts low fibrinogen level. Therefore in cholestatic liver disease, MA is a useful independent predictor of low fibrinogen level. We also found the only significant

predictor of thrombotic complication in non-cholestatic liver disease patients is a lower INR when compared with other cirrhotic patients (p = 0.04). RL VAN LEEST,1 AT DEV,1,2 F RUSLI,1 S PIANKO,1 W SIEVERT,1 S LEE,1 V KNIGHT,1 DT RATNAM1,2 Gastroenterology and Hepatology Unit, Monash Medical Centre1, Department of Medicine, Monash University2 Background and aim: Entecavir is now a 1st line therapeutic option for chronic Hepatitis B (CHB).

However, most of the evidence is reliant on controlled phase III trials or real world data in treatment naïve populations. This may not reflect its true efficacy in the treatment experienced population. This study aims to document the real medchemexpress world experience of using ETV in an Australian cohort and compares nucleoside analogue naïve patients to those exposed to other agents. Methods: 175 CHB patients at a tertiary centre with annual viral loads treated with Entecavir for 6 months or more were identified retrospectively through pharmacy and clinic records. Baseline demographic data and progressive 6 monthly pathology, fibroscan and imaging reports in addition to clinic notes were reviewed. Treatment outcomes were defined as time to undetectable viral load, time to viral load under 360 IU, new advanced cirrhosis or HCC and time to eAg seroconversion. Interim results: HBeAg positive: 77 patients (70.1% male, 63.6% treatment naïve, 76.6% Asian ethnicity, average age 45.8 years). Median ALT 42.5 IU/L, 23% advanced fibrosis. HBeAg negative: 95 patients (74.7% male, 84.2% treatment naïve, 68.4% Asian ethnicity, median age 54.8 years). Median ALT 30.5 IU/L, 37.9% advanced fibrosis.